Lakefront Biotherapeutics revenue and financials
€25.90Change from previous close: −1.97%Absolute change: −€0.52
In the fiscal year ended December 2025, Lakefront Biotherapeutics reported revenue of €1.11B (+303.50% year over year). Net income was €320.88M, a net margin of 28.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +303.50%
- 2025 vs 2024
- Net income growth
- +333.15%
- 2025 vs 2024
- Net margin
- 28.9%
- 2024: 26.9%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -34.1 | -82.8 | -47.5 | -62.6 | -109 | — |
| Capital expenditure | -0.0 | -0.1 | -1.6 | -2.9 | -4.2 | — |
| Investing cash flow | 101 | 61.5 | 72.6 | 56.7 | 74.7 | — |
| Financing cash flow | -3.9 | -0.5 | -0.4 | -1.3 | -0.6 | — |
| Debt repaid | -1.1 | -0.5 | -0.4 | -1.3 | -0.6 | — |
| Effect of exchange rates | 5.8 | 0.7 | -1.3 | -0.1 | -1.7 | — |
| Net change in cash | 63.4 | -21.8 | 24.8 | -7.1 | -34.7 | — |
| Free cash flow | -34.1 | -82.9 | -49.1 | -65.5 | -113 | — |